Essen Biotech

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
CD123 / CD33Cell therapy
Acute Myeloid Leukemia
Phase 1/2
Tumor antigen menu (TROP2, MSLN, B7-H3, HER2)Cell therapy
Solid Tumors
Phase 1/2
Personalized, biomarker-guided allogeneic chimeric antigen receptorCell therapy
Solid Tumors

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
EB-SELECT Single-Target CAR-NK Cells + EB-SELECT Dual-Target CAR-NK CellsPhase 1/2Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate Cancer - Recurrent …
Est. primary completion 2027-12-28 · NCT07410494 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.